Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
|
|
NANOVIRICIDES, INC. (NNVC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"LICENSE AGREEMENT THIS LICENSE AGREEMENT is made at Kolhapur on March 10, 2023 by and Between NANOVIRICIDES, INC. a Company incorporated under the laws of the State of Nevada, and having its registered office at 1 Controls Drive, Shelton, CT 06484 and its successors and assigns with offices And M/S KARVEER MEDITECH PRIVATE LIMITED a company incorporated under Companies Act, 2013 and having it registered office at plot No. 34, Vijaya Nagar, Near Shahu Naka, Ujalaiwadi, Kolhapur, Taluka-Karveer, District-Kolhapur, Maharashtra, India 416004 and its successors and assigns and all of whom are at times referred to as the "Parties". WHEREAS, Karveer is engaged in conducting research and development in the fields of pharmaceuticals and related activities, and has the necessary skill, experience, e..." |
|
| 02/13/2023 |
8-K
| Quarterly results |
| 12/22/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 10/11/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"EXTENSION TO EMPLOYMENT AGREEMENT This Extension to Employment Agreement effective as of July 1, 2022, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 , and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 . WHEREAS, the Parties entered into that certain Employment Agreement on July 11, 2018 which expired pursuant to its terms on June 30, 2021 which was subsequently extended to June 30, 2022 ; WHEREAS, the parties hereto desire to extend the term of the Employment Agreement and to add to and/or revise the terms and conditions of the Employment Agreement; and WHEREAS, the Parties hereto desire that all other terms and conditions of the Employment Agreement not specifically amended hereby will remain in full force and ..." |
|
| 11/26/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 09/21/2021 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 09/15/2021 |
8-K
| Quarterly results |
| 12/10/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/19/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/04/2020 |
8-K
| Quarterly results |
| 08/03/2020 |
8-K
| Quarterly results |
| 07/13/2020 |
8-K
| Quarterly results |
| 06/04/2020 |
8-K
| Resignation/termination of a director |
| 05/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Opinion of McCarter & English LLP",
"Form of Securities Purchase Agreement by and between NanoViricides, Inc. and certain purchasers",
"Placement Agent Agreement, by and between among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc",
"NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering Shelton, Connecticut -- May 21, 2020 -- NanoViricides, Inc. , a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 1,400,000 shares of its common stock at a price of $7.30 per share, for aggregate gross proceeds of approximately $10.22 million, in a registered direct offering. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc., are acting as co-placement agents for the offering. The offering is expected to close on or about May 22, 2020, subject to the satisfaction of customary closing ..." |
|
| 05/19/2020 |
8-K
| Appointed a new director|
Docs:
|
"Director Retainer Agreement, between the Company and Mr. Rokita",
"Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. SHELTON, CONNECTICUT -- May 18, 2019 -- NanoViricides, Inc. , a leader in developing novel nanomedicines to treat viral diseases, announced today that Honorable Mr. Todd Rokita, J.D., former member of the U.S. House of Representatives from Indiana, has joined the Company’ s Board of Directors, effective May 15, 2020, as an independent director. He was also appointed as a member of the Board’ s Nomination Committee and Compensation Committee. Most recently, Mr. Rokita has been nominated by President Trump to the Board of Directors of the National Railroad Passenger Corporation , pending U.S. Senate Confirmation. He is currently co-owner and General Counsel and Vice President of External Affairs, Apex Be..." |
|
| 05/14/2020 |
8-K
| Quarterly results |
| 03/20/2020 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 02/11/2020 |
8-K
| Quarterly results |
| 01/28/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 01/27/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 01/02/2020 |
8-K/A
| Quarterly results |
| 12/19/2019 |
8-K
| Quarterly results |
| 12/13/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders SHELTON, CONNECTICUT -- December 9, 2019 -- NanoViricides, Inc. , a global leader in nanomedicines against viruses, held its annual meeting of shareholders of the Company on Saturday, December 7th, 2019 at 10:00 a.m., Eastern Daylight Time. The meeting was held at the Sheraton Stamford Hotel, 700 East Main Street, Stamford Connecticut 06901. Upon adjournment of the business portion of the meeting, it was opened for questions from shareholders. In response to questions from shareholders regarding a timeline for the Company’ s first IND filing with the US FDA, Dr. Diwan reported that the timeline was extremely dependent on external collaborators, and as such, the Company c..." |
|
| 11/05/2019 |
8-K
| Quarterly results |
| 09/26/2019 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 08/01/2019 |
8-K
| Resignation/termination of a director |
| 06/10/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/01/2019 |
8-K
| Quarterly results |
| 02/01/2019 |
8-K
| Quarterly results |
| 12/07/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 10/31/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/23/2018 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 05/04/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office... |
|
|
|